Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Acuity, Intradigm Working On Topical VEGF Inhibitor

June 10, 2005

By Jennifer Boggs

Biobanks seen accelerating move to personalized medicine

June 9, 2005

By Jennifer Boggs

Osiris brings in $50M to fund stem cell-based therapeutics

June 9, 2005

By Jennifer Boggs

Osiris Brings In $50M To Fund Stem Cell-Based Therapeutics

June 9, 2005

By Jennifer Boggs

Osiris Brings In $50M To Fund Stem Cell-Based Therapeutics

June 9, 2005

By Jennifer Boggs

BPersonalized iobanking Key To Future Of Medicine

June 8, 2005

By Jennifer Boggs

BPersonalized iobanking Key To Future Of Medicine

June 8, 2005

By Jennifer Boggs

Visudyne, Macugen, Lucentis; Wet AMD Landscape Changing

June 7, 2005

By Jennifer Boggs

Visudyne, Macugen, Lucentis; Wet AMD Landscape Changing

June 7, 2005

By Jennifer Boggs

Ziopharm Raises $18M In Series A For Cancer Drugs

June 6, 2005

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...